Peptide buyer's glossary.

What is FDA Section 503A and how does it apply to peptides?

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies in the United States. To use a non-FDA-approved active pharmaceutical ingredient (API) in compounding under 503A, the substance must appear on the FDA's 503A Bulks List or have a USP/NF monograph. Peptides such as BPC-157, KPV, and others are currently under FDA Pharmacy Compounding Advisory Committee (PCAC) review for the 503A Bulks List.

What is the difference between FDA 503A and 503B?

503A covers patient-specific compounding by licensed pharmacies; 503B covers registered Outsourcing Facilities that produce sterile compounded preparations in larger batches without patient-specific prescriptions. 503B facilities must comply with cGMP (current Good Manufacturing Practice) and FDA inspection, similar to drug manufacturers, while 503A pharmacies are regulated primarily by state boards of pharmacy.

What is an FDA Drug Master File (DMF)?

A Drug Master File is a confidential submission to the FDA that contains information about facilities, processes, or articles used in manufacturing drug products. For peptide APIs, suppliers typically file a Type II DMF, which the FDA can reference when reviewing a drug application from the supplier's customers. A DMF on file is a strong signal that the manufacturer is prepared for FDA scrutiny.

What is the FDA PCAC and why does it matter for peptide buyers?

The Pharmacy Compounding Advisory Committee is an FDA advisory body that recommends which bulk drug substances should be added to or removed from the 503A and 503B bulks lists. PCAC decisions directly shape which peptides US compounding pharmacies can legally use; the July 2026 PCAC meeting is reviewing seven peptides including BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon.

How does the European Medicines Agency regulate peptide suppliers?

The EMA oversees medicinal product authorization in the European Union. Peptide API suppliers serving EU customers typically operate under EU GMP guidelines, with sterile manufacturing required to comply with EU GMP Annex 1 (revised 2022). Suppliers may register an Active Substance Master File (ASMF) — the European equivalent of an FDA DMF.

What is EU GMP Annex 1?

EU GMP Annex 1 (revised August 2022, effective August 2023) is the European GMP standard governing the manufacture of sterile medicinal products. It establishes requirements for contamination control strategy, cleanroom classification (Grade A through D), aseptic processing, lyophilization, and continuous environmental monitoring. Suppliers shipping sterile peptide products to EU markets are expected to align with Annex 1.

What is ICH Q7 and why is it cited on peptide CoAs?

ICH Q7 is the International Council for Harmonisation guideline on Good Manufacturing Practice for active pharmaceutical ingredients (APIs). It establishes expectations for quality systems, process controls, validation, change management, and documentation across the API lifecycle. Peptide manufacturers reference ICH Q7 to signal that synthesis, purification, and release are performed under GMP-equivalent controls.

What does ICH Q11 cover for peptide manufacturing?

ICH Q11 describes approaches to the development and manufacture of drug substances, including chemical entities and biotechnological products. For peptides, it provides the framework for defining critical quality attributes (CQAs), critical process parameters (CPPs), and the control strategy for synthesis and purification. ICH Q11 is the reference for justifying starting materials and process design.

What does ISO 9001:2015 certification mean for a peptide supplier?

ISO 9001:2015 is the international standard for quality management systems. Certification means an accredited third-party body has audited the supplier's documented procedures for customer focus, leadership, process management, performance evaluation, and continuous improvement. ISO 9001 is process-based and applies across industries — it is necessary but not sufficient for pharmaceutical-grade peptide supply.

What is the difference between ISO 7 and ISO 8 cleanrooms?

ISO 14644-1 classifies cleanrooms by maximum allowable airborne particle counts. ISO 7 allows up to 352,000 particles ≥0.5 μm per cubic meter (equivalent to Class 10,000); ISO 8 allows up to 3,520,000 particles ≥0.5 μm per cubic meter (Class 100,000). Sterile peptide fill-finish operations typically occur in ISO 5 (Grade A) inside an ISO 7 (Grade B) background; non-sterile compounding may be performed in ISO 8.

What should a peptide Certificate of Analysis include?

A complete peptide COA documents product identity, batch identification, and the analytical results against specifications. At minimum, expect: product name, CAS number, batch/lot number, manufacture and re-test dates, appearance, identity by HPLC retention time and mass spectrometry, purity by HPLC, water content (Karl Fischer), counter-ion content, peptide content (amino acid analysis), residual solvents, bacterial endotoxin (LAL), and microbial limits. Each test should reference the method (often a USP chapter).

How is HPLC used to test peptide purity?

Reversed-phase HPLC (RP-HPLC) separates a peptide sample by hydrophobicity, producing a chromatogram where the main peak is the target peptide and smaller peaks are impurities or sequence variants. Purity is calculated as the main-peak area as a percentage of total integrated area (area-%). Research-grade peptides are typically released at ≥98%; high-purity API-grade material at ≥99% and individual impurities ≤0.5%. Method validation follows USP <1225>.

Why is mass spectrometry on every peptide COA?

Mass spectrometry confirms peptide identity by measuring molecular mass to within fractions of a Dalton. Electrospray ionization (ESI-MS) is the most common technique for peptides; matrix-assisted laser desorption/ionization (MALDI) is used for larger peptides and proteins. The observed mass is compared to the theoretical mass calculated from the sequence — a match within ±0.5 Da confirms the correct primary structure.

What is the LAL test and what does it measure?

The Limulus Amebocyte Lysate test detects bacterial endotoxins (lipopolysaccharides from Gram-negative bacterial cell walls) by their reaction with a clotting enzyme derived from horseshoe crab blood. For injectable peptides, endotoxin must be below pharmacopeial limits — USP <85> defines kinetic chromogenic, kinetic turbidimetric, and gel-clot methods. A typical specification for research peptides is ≤0.25 EU/mg.

What does Karl Fischer measure on a peptide COA?

Karl Fischer titration determines the water content of a lyophilized peptide. Excess moisture accelerates degradation (hydrolysis, oxidation, aggregation) and shortens shelf life, so most peptide specifications require ≤5.0% water content, often ≤3%. The method is described in USP <921>.

What does amino acid analysis report on a peptide COA?

Amino acid analysis hydrolyzes the peptide into its constituent amino acids and quantifies each. This serves two purposes: confirming the amino acid composition matches the expected sequence, and calculating peptide content (the actual peptide mass per gram of dry product, after subtracting water, counter-ions, and impurities). True peptide content is typically 70-90% of the gross mass — the rest is acetate or TFA counter-ions and residual water.

How is peptide sequence verified?

Primary sequence is confirmed by LC-MS/MS (tandem mass spectrometry), which fragments the peptide and reads the masses of the fragment ions to reconstruct the sequence. Edman degradation, an older N-terminal sequential cleavage method, is used for shorter peptides or when LC-MS/MS is inconclusive. Sequence verification is performed at development and is reconfirmed periodically; standard release tests rely on retention-time match and intact-mass MS.

What does USP Chapter <797> require for compounded peptides?

USP <797> establishes the minimum standards for compounding sterile preparations in the United States, including pharmacy cleanroom design, personnel training, garbing, environmental monitoring, beyond-use dating (BUD), and quality assurance. Peptide suppliers serving compounding pharmacies provide documentation aligned with <797> so receiving pharmacies can extend BUD past the default conservative limits.

What is USP <1225> and why is it referenced on peptide COAs?

USP <1225> describes how analytical procedures are validated — covering specificity, linearity, accuracy, precision (repeatability and intermediate), detection limit, quantitation limit, range, and robustness. A peptide COA citing USP <1225> tells the customer that the HPLC, mass spec, and other tests on the document were performed using methods qualified to compendial standards.

How are peptides manufactured?

Most modern peptide APIs are made by solid-phase peptide synthesis (SPPS), invented by Merrifield in 1963. The peptide chain is built one amino acid at a time on an insoluble polymer support, using Fmoc or Boc protecting groups and standardized coupling/deprotection cycles. After full chain assembly, the peptide is cleaved from the support, deprotected, and purified — typically by reversed-phase HPLC — before lyophilization.

Why are peptides supplied as lyophilized powder?

Lyophilization (freeze-drying) removes water by sublimation under vacuum, leaving a stable solid cake. Lyophilized peptides have substantially longer shelf life than aqueous solutions — typically 24 months at -20°C versus weeks to months in solution — because hydrolysis, oxidation, and aggregation pathways all slow dramatically in the solid state.

What is a peptide counter-ion and why does it matter?

Most peptides carry basic residues (Lys, Arg, His) that exist as cations at neutral pH, so the dry powder is always a salt with an associated anion. Common counter-ions are acetate (cleanest for injection), trifluoroacetate (TFA, residual from HPLC purification), and hydrochloride. Acetate-form material is preferred for injectable use; TFA-form is acceptable for research applications but is typically converted to acetate for pharmaceutical use.

What does a peptide stability program test?

A stability program measures degradation over time under defined storage conditions, in line with ICH Q1A(R2). Accelerated stability runs at 40°C / 75% relative humidity for up to 6 months; long-term stability runs at the labeled storage condition (typically -20°C or 2-8°C) for the proposed re-test period. Tests at each pull point include HPLC purity, mass spec identity, water content, and appearance.

How is a synthetic peptide purified?

After cleavage from the synthesis resin, crude peptide is purified by preparative reversed-phase HPLC, typically on C18 silica with an acetonitrile/water gradient buffered by TFA or formic acid. Multiple injections may be needed to process a kilogram-scale crude batch. Fractions are pooled based on analytical HPLC purity and counter-ion exchanged before final lyophilization.

What is a typical MOQ for B2B peptide orders?

MOQ varies widely by peptide complexity and demand. Catalog research peptides typically have MOQs in the range of 100-1,000 vials per SKU; custom-synthesized peptides may start at 10 grams of bulk material. Established commercial buyers can often negotiate lower MOQs in exchange for forecasted recurring orders.

Which Incoterms are used for international peptide shipments?

The ICC Incoterms 2020 define cost and risk transfer points between seller and buyer. The most common terms for peptide shipments: EXW (Ex Works — buyer collects from supplier's facility), FOB (Free On Board — seller delivers to port), CIF (Cost, Insurance, Freight — seller pays freight to destination port), and DDP (Delivered Duty Paid — seller handles all costs through customs clearance at buyer's door). DDP is preferred for buyers who want a single all-inclusive landed price.

What lead times are typical for catalog versus custom peptides?

Catalog peptides held in inventory ship within 1-2 weeks of order confirmation. Make-to-order catalog peptides typically require 3-4 weeks. Custom-synthesized peptides depend on length, modifications, and scale: 4-6 weeks for standard sequences up to 30 residues; 6-12 weeks for longer or heavily-modified sequences requiring methodology development.

What does OEM mean for peptide products?

Original Equipment Manufacturer (OEM), in peptide industry usage, means the supplier manufactures product that the buyer markets under their own brand. This typically includes custom vial labeling, custom secondary packaging (boxes, inserts, IFUs), and optionally customer-specific formulation or fill volumes. OEM is common in the medical aesthetics and cosmetic peptide segments.

Do peptides need cold-chain shipping?

Lyophilized peptides are stable at ambient temperature for the duration of typical international shipping (3-7 days) when packaged with phase-change materials. Long-term storage requires -20°C for most peptides. Cold-chain shipping (gel packs, dry ice) is used for temperature-sensitive analogs, large bulk shipments where ambient transit times might exceed a week, or when the buyer specifically requires temperature-logged shipping.